Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.